Mathieu S Bolhuis
Overview
Explore the profile of Mathieu S Bolhuis including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
45
Citations
442
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Marongiu S, Bolhuis M, Touw D, Kneyber M
Pediatr Rep
. 2025 Jan;
17(1.
PMID: 39846522
Objectives: Intravenous midazolam is widely used for sedation in critically ill children. Sometimes, these children develop a paediatric delirium (PD). Our aim was to determine the relationship between midazolam serum...
2.
Overduin R, Grunert S, Besouw M, Bolhuis M, Groen J, Schreuder A, et al.
J Inherit Metab Dis
. 2024 May;
47(5):1018-1027.
PMID: 38802119
Renal proximal tubulopathy in Fanconi-Bickel syndrome is caused by impaired basolateral glucose transport via GLUT2 and consequently, intracellular accumulation of glucose and glycogen. SGLT2 inhibitors act on apical glucose reabsorption...
3.
Derks T, Venema A, Koller C, Bos E, Overduin R, Stolwijk N, et al.
J Inherit Metab Dis
. 2024 Jan;
47(2):244-254.
PMID: 38185897
Off-label repurposing of empagliflozin allows pathomechanism-based treatment of neutropenia/neutrophil-dysfunction in glycogen storage disease type Ib (GSDIb). From a value-based healthcare (VBHC) perspective, we here retrospectively studied patient-reported, clinical and pharmacoeconomic...
4.
Keutzer L, Mockeliunas L, Sturkenboom M, Bolhuis M, Akkerman O, Simonsson U
Pharmaceuticals (Basel)
. 2023 Nov;
16(11).
PMID: 38004440
Long-term usage of linezolid can result in adverse events such as peripheral neuropathy, anemia and thrombocytopenia. Therapeutic drug monitoring data from 75 drug-resistant tuberculosis patients treated with linezolid were analyzed...
5.
Mian P, Bolhuis M, Maurer J, van Stuijvenberg M
Mol Cell Pediatr
. 2022 Dec;
9(1):20.
PMID: 36542240
Insulin is used to treat neonatal hyperglycaemia when blood glucose concentrations are consistently high, and to treat neonatal diabetes. Within this brief report, a review of the existing literature is...
6.
Ghimire S, Iskandar D, van der Borg-Boekhout R, Zenina M, Bolhuis M, Kerstjens H, et al.
Eur Respir J
. 2022 Nov;
60(6).
PMID: 36356974
No abstract available.
7.
Abolhassani-Chimeh R, Akkerman O, Saktiawati A, Punt N, Bolhuis M, Subronto Y, et al.
Antimicrob Agents Chemother
. 2022 Jun;
66(7):e0000322.
PMID: 35727060
Pyrazinamide is one of the first-line antituberculosis drugs. The efficacy of pyrazinamide is associated with the ratio of 24-h area under the concentration-time curve (AUC) to MIC. The objective of...
8.
Mockeliunas L, Keutzer L, Sturkenboom M, Bolhuis M, Hulskotte L, Akkerman O, et al.
Pharmaceutics
. 2022 Apr;
14(4).
PMID: 35456587
Linezolid is an efficacious medication for the treatment of drug-resistant tuberculosis but has been associated with serious safety issues that can result in treatment interruption. The objectives of this study...
9.
Berends A, Bolhuis M, Nolte I, Buitenwerf E, Links T, Timmers H, et al.
Biomedicines
. 2022 Apr;
10(4).
PMID: 35453646
Background: Presurgical treatment with an α-adrenergic receptor blocker is recommended to antagonize the catecholamine-induced α-adrenergic receptor mediated vasoconstriction in patients with pheochromocytoma or sympathetic paraganglioma (PPGL). There is, however, a...
10.
Ter Beek L, Bolhuis M, Jager-Wittenaar H, Brijan R, Sturkenboom M, Kerstjens H, et al.
BMJ Open
. 2022 Mar;
11(12):e049777.
PMID: 35344503
Objectives: Malnutrition is associated with a twofold higher risk of dying in patients with tuberculosis (TB) and considered an important potentially reversible risk factor for failure of TB treatment. The...